略晓薛
Lv2
180 积分
2022-12-10 加入
-
VIR-2218 (elebsiran) plus pegylated interferon-alfa-2a in participants with chronic hepatitis B virus infection: a phase 2 study
9天前
已关闭
-
Control of Hepatitis B Virus with Imdusiran, a Small Interfering RNA Therapeutic
25天前
已完结
-
Phase 1b/2a randomized study of heterologous ChAdOx1-HBV/MVA-HBV therapeutic vaccination (VTP-300) as monotherapy and combined with low-dose nivolumab in virally-suppressed patients with chronic hepatitis B
1个月前
已完结
-
Sequential Peg-IFN after bepirovirsen may reduce post-treatment relapse in chronic hepatitis B
1个月前
已完结
-
In vivo reduction of hepatitis B virus antigenemia and viremia by antisense oligonucleotides
6个月前
已完结
-
A novel, small anti-HBV compound reduces HBsAg and HBV-DNA by destabilizing HBV-RNA
7个月前
已完结
-
Class a capsid assembly modulator RG7907 clears HBV-infected hepatocytes through core-dependent hepatocyte death and proliferation
1年前
已完结
-
Discovery of Linvencorvir (RG7907), a Hepatitis B Virus Core Protein Allosteric Modulator, for the Treatment of Chronic HBV Infection
1年前
已完结
-
Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial
1年前
已完结
-
Safety, pharmacokinetics, and antiviral activity of ABI‐H2158, a hepatitis B virus core inhibitor: a randomized, placebo‐controlled Phase 1 study
1年前
已完结